The actions of a novel lipoprotein lipase activator, NO-1886, in hypertriglyceridemic fructose-fed rats.
High circulating fasting and prandial triglyceride levels are associated with both insulin resistance and the development of cardiovascular disease. The aim of this investigation was to study the effects of NO-1886, a novel lipoprotein lipase (LPL) activator, on triglyceride levels, fat oxidation, and glucose tolerance in fructose-fed rats, a hypertriglyceridemic model of insulin resistance. Adult male Wistar rats were fed for 4 weeks with a high-starch diet or a high-fructose diet without and with NO-1886 (50 mg x kg[-1] x d[-1] orally). Fructose feeding increased plasma triglyceride levels, an effect that was ameliorated by NO-1886 treatment (week 1/week 4: starch-fed, 2.4 +/- 0.1/2.8 +/- 0.2 mmol/L; fructose-fed, 3.6 +/- 0.5/5.5 +/- 0.5; fructose + NO-1886, 2.7 +/- 0.2/3.6 +/- 0.3). The mean 24-hour respiratory quotient (RQ) was significantly lower in the fructose + NO-1886 group compared with fructose-fed rats, indicating increased oxidation of fat. Fructose feeding elevated liver triglyceride levels by 74% (P < .01), an effect not altered by NO-1886. Red and white quadriceps hindlimb muscle triglyceride levels were not different between groups. Glucose tolerance (intravenous test in long-term cannulated rats) was mildly deteriorated and fasting insulin and glucose levels were elevated in fructose-fed rats, effects which were ameliorated by NO-1886. In conclusion, in the fructose-fed rat model of hypertriglyceridemia and insulin resistance, addition of a LPL activator reduced circulating triglyceride levels without causing increased muscle triglyceride accumulation or deterioration in glucose tolerance. LPL activators may prove to be a fruitful avenue to explore in the search for new therapeutic agents in the treatment of dyslipidemias and insulin resistance.
Hara
T
T
Department of Endocrinology, Royal Prince Alfred Hospital, Camperdown, Australia.
Cameron-Smith
D
D
Cooney
G J
GJ
Kusunoki
M
M
Tsutsumi
K
K
Storlien
L H
LH
D000818:Animals; D001549:Benzamides / Q000494:pharmacology* / Q000627:therapeutic use; D004789:Enzyme Activation / Q000187:drug effects; D005632:Fructose / Q000008:administration & dosage*; D005947:Glucose / Q000378:metabolism; D015228:Hypertriglyceridemia / Q000188:drug therapy* / Q000378:metabolism; D008071:Lipoprotein Lipase / Q000502:physiology*; D008297:Male; D009943:Organophosphorus Compounds / Q000494:pharmacology* / Q000627:therapeutic use; D011659:Pulmonary Gas Exchange / Q000187:drug effects; D051381:Rats; D017207:Rats, Sprague-Dawley; D014280:Triglycerides / Q000378:metabolism; D015430:Weight Gain / Q000187:drug effects
D001549:Benzamides; D009943:Organophosphorus Compounds; D014280:Triglycerides; C082137:4-diethoxyphosphorylmethyl-N-(4-bromo-2-cyanophenyl)benzamide; D005632:Fructose; D008071:Lipoprotein Lipase; D005947:Glucose